MedInCell Stock: More than 2% Rebound in Still Fragile Technical Context
MedInCell's stock significantly advanced this Thursday, February 19, trading at 24.50 euros midday, marking an increase of 2.25% from the previous day. This rebound follows a challenging quarter with a nearly 19.3% decline over three months. However, the Montpellier-based biotech company has shown remarkable annual performance, with a gain of 74.75% over the year.
MedInCell's stock is currently in an intermediate technical zone. The price of 24.50 euros is above the 200-day moving average, set at 22.53 euros, indicating a still bullish long-term trend. However, the stock remains below its 50-day moving average (25.58 euros), suggesting that the medium-term momentum remains under pressure following recent corrections. The RSI, an indicator measuring the relative strength of the ongoing movement, stands at 50, a perfectly neutral level that signals neither overbuying nor overselling. This configuration suggests that the stock is at a balance point, without a marked directional impulse. The most relevant support threshold is at 22.56 euros, close to the 200-day moving average, while the resistance to watch is positioned at 29.20 euros.
Fundamental Outlook
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The upcoming months are crucial for the company specialized in long-duration drug injection technologies. The financial calendar schedules the publication of the annual results for the fiscal year 2025-2026 on June 16, an event that will assess the commercial and operational trajectory of the group following the launch of its first products. The general assembly is scheduled for September 10, 2026, followed by the communication of the results for the first half of 2026-2027 on December 8. These milestones will provide increased visibility on MedInCell's ability to turn its clinical advances and partnerships into recurring revenues. With a beta of 0.03, the stock is distinguished by an extremely low correlation with benchmark indices, reflecting a value profile more driven by its own catalysts than by general market conditions.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
